For families facing high-grade glioma (HGG), the deadliest childhood brain cancer, the diagnosis often feels like a storm: dark, fast, and overwhelming. Treatments are limited, harmful, and too often ineffective. For more than 40 years, progress has been slow, treatments have remained painfully toxic, and children have borne the weight of a system that simply did not have the tools, data, or alignment it needed to change the forecast.

But this moment is different. And for the first time ever, thanks to the influence, funding, and relentless advocacy of Bridge To A Cure Foundation, the entire pediatric brain tumor community is coming together behind a series of unified goals:

• Drive shared data collection, access, and harmonization
• Cure high-grade glioma
• Pursue non-toxic treatments
• Leverage the full power of data and AI to get there faster

This is the culmination of the Bridge To A Cure mission from day one: to unite and transform the childhood cancer community’s approach to research with the goal of cutting the childhood cancer death rate by 50% by 2030.

Why HGG Has Been So Hard to Cure — and Why That’s Changing

High-grade glioma moves quickly. It infiltrates healthy brain tissue, resists nearly all available therapies, and evolves fast enough to outrun scientific understanding. For years, researchers lacked the visibility needed to track the disease’s behavior, not because they lacked dedication, but because they lacked something fundamental: shared, high-quality data.

Each hospital held only a few cases. Each research center saw only fragments. As a result, discovery moved slowly, and families waited under a sky that didn’t seem to clear.

Thanks to the combined momentum of our foundation’s advocacy and the Children’s Brain Tumor Network (CBTN), that reality has shifted. And by bringing dozens of childhood cancer foundations and more than 35 pediatric institutions together and uniting their data, imaging, biospecimens, and expertise, CBTN has created the largest collaborative pediatric brain cancer community in the world, and with it, new clarity, new insights, and new momentum.

This shared ecosystem has set the stage for something once unimaginable: real insight, real collaboration, and real possibility.

The BTAC–CBTN Partnership: Preparing 900 Datasets for a Brighter Future

Among the most extraordinary achievements of our network is the contribution made by 900 children with HGG, whose families shared clinical records, imaging, and tumor data in the hope that no other family would weather the storm alone.

To honor their courage, Bridge To A Cure Foundation is funding the work needed to prepare these 900 datasets to FDA gold-standard quality, the essential step for:

• powering new AI-driven research,
• supporting regulatory submissions,
• designing smarter, safer clinical trials, and
• moving toward less-toxic treatments that protect childhood.

This work turns raw information into a stable foundation where new discoveries can finally take root.

Bridge To A Cure is committed to completing the HGG dataset validation within a single year—an ambitious yet essential goal. By the end of 2026, this data will fully power the RADIANT AI pediatric research platform, enabling scientists to detect patterns no human eye could see and accelerating the development of safer, more effective therapies children urgently need.

A Gathering of Leaders: The SU2C High-Grade Glioma Summit

This January marks a pivotal shift. Stand Up To Cancer (SU2C) will host the first-ever national pediatric High-Grade Glioma Summit, bringing together leaders in oncology, genomics, AI, and clinical innovation.

This transformative Summit reflects the growing momentum across the entire field, shaped in part by years of Bridge To A Cure’s advocacy, coalition-building, and insistence that the community align around curing pediatric glioblastoma. The call for unity, shared data, and non-toxic treatments, championed consistently by Bridge To A Cure, helped create the conditions for a gathering of this scale to become a national priority. Summit attendees will come together, in person, to meet around these shared goals and collaborate on ways to achieve them.

Bridge To A Cure President Robert (Bob) Martin has been invited to join as a panelist, representing:

• the voice of families,
• the need for scientific collaboration,
• the promise of data-driven research, and
• the urgency of developing non-toxic treatments.

Bob’s leadership ensures the movement to cure HGG remains centered on the children who need it most and the families who have already endured far too many storms.

2026: A Break in the Clouds

Across childhood brain cancer research, the weather pattern is changing:

• Data is no longer siloed.
• Scientists are no longer working alone.
• AI is no longer a distant promise — it’s becoming a real tool.
• Families’ contributions are finally being honored through action.
• Institutions are aligning under shared momentum.

These are rays of light that are bursting through years of cloudy progress. And as the validated HGG dataset comes online in 2026, paired with Radiant AI insights and guided by collaborations strengthened through the SU2C summit, we approach a horizon that has remained out of reach for far too long: the possibility of safer, smarter, more effective treatments for children with high-grade glioma.

How You Can Help

Preparing the HGG dataset is not optional. It’s the foundational step that makes every discovery possible. And now, thanks to a $50,000 matching gift from a generous anonymous donor, every gift through December 31 is doubled.

This funding drives a new dawn for kids with cancer through:

• FDA-grade data validation
• AI-enabled research through RADIANT
• Collaborative scientific alignment heading into 2026
• BTAC’s advocacy at the SU2C summit
• And progress toward the non-toxic treatments children urgently need

Your support doesn’t just fund a project. It brings light into a space that has lived under clouds for far too long.

A Brighter Horizon for Children

We cannot change the past, but together we are reshaping the future, one dataset, one discovery, one act of generosity at a time. And families who have endured the darkest days are beginning to see the possibility of a brighter tomorrow.

As we enter 2026, hope is no longer just an idea — it’s our direction.

Double your impact. Fulfill the promise.
Donate through December 31: bit.ly/BTAC-double-impact

WINSTON ELY

Originally published by PR Newswire, November 20, 2025.

Bridge To A Cure Foundation announces the appointment of Winston Ely to its Board of Directors. Ely, a Brooklyn-based designer and developer, brings more than 30 years of experience in architecture, sustainable design, and community-focused development.

Ely is the Owner and Creative Director of WE Design and Founder of WE Develop, where he leads residential and mixed-use projects with an emphasis on thoughtful planning and environmental responsibility. He also serves as a Green Infrastructure Fellow for the Design Trust for Public Space, contributing expertise to efforts focused on improving stormwater management and water quality across New York City.

Ely’s appointment to the organization’s Board of Directors carries personal meaning. Bridge To A Cure Foundation was established in memory of his daughter, Clara Ely, whose life continues to inspire the organization’s mission to accelerate progress in childhood cancer research through data integration, collaboration, and innovation.

“Winston brings valuable perspective as both a parent and an experienced leader in systems-based problem-solving,” said Bob Martin, Founder and Chair of Bridge To A Cure Foundation. “His insight will support our efforts to expand collaboration and strengthen the infrastructure needed to advance more effective pediatric brain cancer research.”

As a member of the Board, Ely will support strategic planning and governance efforts that align with the foundation’s focus on driving scientific collaboration and improving outcomes for children facing brain cancer.

“I am honored to join the Board of Bridge To A Cure Foundation in Clara’s memory,” shared Ely. “I look forward to contributing to efforts that connect people, data, and ideas to help accelerate meaningful progress for children and families affected by cancer.”

Ely resides in Brooklyn with his wife, Tricia Martin, and their children, Keira and Yeimer. He holds a BA in Art and Environmental Design from the University of Vermont and a Master’s in Architecture from the University of Oregon.

About Bridge To A Cure Foundation

Bridge To A Cure Foundation is accelerating the pace of childhood cancer research by championing data integration, collaboration, and innovation. By breaking down silos and investing in platforms that connect researchers, clinicians, and families, the foundation strives to ensure that every child and family can benefit from the full power of science, technology, and shared knowledge. To learn more, visit BridgeToACure.org.

Even among other pediatric brain tumors, high-grade glioma (HGG) is a disturbing diagnosis. It is the deadliest form of pediatric brain cancer and among the hardest to treat. These tumors grow deep within the brain, infiltrating healthy tissue so quickly and diffusely that even the best neurosurgeons cannot remove them completely.

For children and families, the statistics are staggering:

• HGG accounts for roughly 20 percent of all pediatric brain tumor deaths.
• Average survival is often less than two years from diagnosis.
• Existing treatments—surgery, chemotherapy, radiation—are toxic and largely ineffective, leaving those who survive with lasting physical and cognitive harm.

Despite decades of effort, survival rates for HGG have barely improved. Each year, more families hear the same heartbreaking words: “There are no good options left.”

Why Progress Has Been Sluggish

The traditional model of cancer research has unintentionally slowed discovery. For decades, hospitals and labs have stored patient samples and data within their own walls, developing therapies in isolation. This siloed approach meant that no single institution had enough cases—or enough diverse data—to reveal the full picture of how HGG grows, mutates, and resists treatment.

Without large, harmonized datasets, scientists could not:

• Identify the subtle biological patterns that differentiate tumor subtypes.
• Use artificial intelligence (AI) to predict treatment response.
• Design clinical trials fast enough to keep pace with the disease.

In short, every child’s story remained trapped inside a separate data silo.

Breaking Down Barriers Through Collaboration

The Children’s Brain Tumor Network (CBTN) has changed that story. CBTN unites more than 35 leading hospitals and research centers around the world, sharing biospecimens, imaging, and clinical data openly through the Pediatric Brain Tumor Atlas—one of the largest, most comprehensive datasets in existence. Bridge To A Cure is an Executive Council member of CBTN, helping to fuel this barrier-breaking momentum.

For the first time ever, researchers can see across institutions, compare results, and build on each other’s work with relative ease. This collaborative, open-science model has already begun to accelerate discoveries across multiple tumor types.

But for HGG—the most aggressive of them all—the work must go even further.

The Next Leap: Making Data FDA-Ready

CBTN now holds the largest open-access collection of HGG data in the world, contributed by 900 brave children and their families. To unleash its full power, this data must be verified, standardized, and connected at a level that meets FDA gold-standard quality—the rigorous benchmark required to design clinical trials, support regulatory submissions, and serve as the foundation for AI-driven discovery.

That is the focus of the Bridge To A Cure Foundation’s flagship initiative: The Clinical Validation of the High-Grade Glioma Cohort.

Through this project, specialists will:

• Clean and lock 900 patient records to regulatory-grade quality.
• Harmonize imaging, molecular, and clinical data across all sites.
• Validate these datasets in real time to inform AI-powered analyses and discoveries.

When complete, this will be the first FDA-ready pediatric brain-cancer dataset—a resource that researchers, clinicians, and regulators worldwide can trust to accelerate safer, more effective therapies.

How This Work Changes Everything

Validated, interoperable data is more than a technical milestone—it is the foundation for cures. With it, scientists can:

• Develop AI models that uncover molecular targets invisible to the human eye.
• Identify drugs that attack tumors while sparing healthy tissue.
• Launch clinical trials faster, guided by real-world evidence.
• Replace the old trial-and-error approach with precision, data-driven care.

For families, this means shorter paths to new therapies and treatments that heal without harm. For researchers, it means an end to guesswork and duplication. For donors, it means every dollar drives measurable, lasting change.

How Donors Fulfill the Promise

Bridge To A Cure Foundation is raising $150,000 to complete CBTN’s transformational work. Every contribution is urgently needed and helps prepare this data for global use, accelerates discovery, innovates through AI, and develops non-toxic therapies.

And now, thanks to a $50,000 matching gift from a generous anonymous donor, every donation made through the end of the year will be doubled.

The 900 children who contributed their data have given all they can. Now it’s our turn to honor that courage by turning data into discovery and discovery into cures.

Double your impact. Fulfill the promise.

Donate at bit.ly/BTAC-double-impact.

In 2024, Bridge To A Cure Foundation turned turbulence into progress. What began as a stormy forecast for childhood cancer research ended with clear signs of brighter days ahead, thanks to a community determined to improve outcomes for kids everywhere.

A Year Defined by Progress

Last year marked critical milestones in Bridge To A Cure’s plan to reduce pediatric brain cancer 50% by 2030.

• Fueled Innovation: We helped advance the M³ scientific approach, integrating multidisciplinary expertise, multiomics data, and multimodal insights to accelerate breakthroughs to cures and cultivate more personalized therapies.
• Expanded Data Access: Our support enabled more than 800 new tissue samples to be processed for the Pediatric Brain Tumor Atlas, now housed in the NIH-funded Kids First Data Resource Center, where it powers discovery alongside 35 other pediatric and rare disease datasets.
• Drove AI-Powered Breakthroughs: Through collaborations like the $10 million ARPA-H RADIANT project, we laid the groundwork for real-time clinical data integration—an innovation that promises to unlock faster, better-informed treatments tailored to each child.
• Catalyzed Safer Therapies: Strategic funding advanced studies in immunotherapy, apoptosis, and angiogenesis—pioneering new ways to fight tumors without devastating side effects.

These aren’t just research terms—they represent real hope for children and families who deserve a future beyond the shadow of cancer.

Robert Martin, Founder and President of Bridge To A Cure Foundation, reflects on this incredible year of progress:

“Our journey began with a promise—one born from love, forged through loss, and carried forward by hope. What started as a vow to one child has become a mission for all: to reduce childhood cancer deaths by 50% by 2030. Together, we are turning storms into sunshine for children everywhere.”

Why It Matters

The truth remains stark: childhood cancer is the leading cause of disease-related death in kids, and most treatments are decades old. But 2024 proved something powerful: collaboration works, data saves lives, and innovation accelerates cures.

The Forecast for 2025: Bold and Clear

Our mission is unwavering: unite and transform the childhood cancer research community to reduce deaths by 50% by 2030. To get there, 2025 is a year of bold initiatives:

• Strengthening Global Data Ecosystems: Invest in platforms that equip researchers across institutions and borders.
• Expanding AI Capabilities: Build AI-powered analytics tools that turn complex data into actionable treatments faster than ever.
• Championing Policy for Progress: Advocate for legislation that sustains research funding and removes barriers to discovery.
• Mobilize the Bridge To A Cure Movement: Engage with families, peer foundations, and industry partners to eliminate silos and amplify impact.

The clouds are breaking, but the work is far from done. Together, we can turn today’s breakthroughs into tomorrow’s cures.

What keeps Bridge To A Cure pushing ahead in 2025? We’re simply Fulfilling the Promise made. You can help us keep our commitment to families facing the devastating effects of brain tumors. Read our 2024 Annual Report. Share our mission. Give to fuel breakthroughs that will save our kids.

Over this past year, Bridge To A Cure has played a key role in accelerating life-saving discoveries for childhood brain tumors through our partnership with the Children’s Brain Tumor Network (CBTN), a worldwide leader in pediatric data collection, sharing, and collaboration.

In fact, every dollar donated through Bridge To A Cure in 2024 strengthened the vital work conducted by our coalition, empowering hundreds of researchers with the tools and infrastructure they need to unlock cures. It further enforces the collaborative spirit that will result in better treatments and, ultimately, a cure for these deadly diseases.

Together, we’re changing how research is conducted and the speed at which discoveries are made.

We’re thrilled to share some of the biggest highlights of 2024:

Expanding Critical Data: With funding from several sources, including Bridge To A Cure, CBTN processed hundreds of new patient samples in 2024, significantly enriching the Pediatric Brain Tumor Atlas. This invaluable resource allows researchers to delve deeper into the unique biology of these tumors, paving the way for targeted and more effective treatments.

Enhancing Global Collaboration: The CAVATICA software platform, a cornerstone of this partnership’s research efforts, supported over 1,500 global research projects in 2024. Upgrades to this essential tool have improved usability and real-time data access, fostering seamless collaboration among researchers worldwide and accelerating the pace of discovery.

Advancing AI-Driven Solutions: With the resources of CBTN and supported by our coalition, we’ve made significant strides in developing AI-ready datasets and predictive models for some of the most challenging types of pediatric brain tumors, including diffuse midline gliomas (DMG) and medulloblastomas. These innovative approaches hold immense promise for deeper insights and the development of new treatment strategies.

Strengthening Pediatric Proteomic Data: CBTN maintains the largest cohort of pediatric proteomic (proteins) data for brain tumors, expanding it by 30% in 2024. This enriched dataset is crucial for advancing personalized medicine and developing treatments tailored to each child’s unique tumor characteristics.

Building A Data-Driven Research Community

In October 2017, Bridge To A Cure Founder Bob Martin met with National Cancer Institute NCI) Director Dr. Ned Sharpless to share his recommendation to build a national childhood cancer database that was easily accessible by researchers. This idea is realized in the Childhood Cancer Data Initiative (CCDI), authorized by Congress just two years later and funded at $50 million annually for 10 years.

This crucial resource was made possible through harmonizing data using a unified lexicon, an endeavor funded by the Bridge To A Cure Foundation through the Pediatric Cancer Data Commons (PCDC). By uniting data from various sources, including the Kids First Data Resource Center, St. Jude Cloud, and the Treehouse Childhood Cancer Data Initiative, CCDI aims to foster a collaborative research environment where scientists can access more data, tools, and resources than ever before.

A RADIANT Approach to Cures

For years, Bridge To A Cure has called to expedite a united approach to scientific discovery through technological advancement. Now, CBTN stands at the forefront of pediatric cancer research, spearheading initiatives like the government-funded RADIANT project. In collaboration with leading technology companies, including Amazon Web Services (AWS), Valsera, and Mulesoft (a SalesForce company), this ambitious initiative aims to integrate AI seamlessly into all aspects of pediatric cancer research. AI and leading-edge technologies are significant aspects of how Bridge To A Cure will achieve our mission of reducing the childhood cancer death rate by 50% by 2030. That’s why we invested $200,000 to seed this vital program. Through this investment, CBTN created patient data pipelines that seamlessly integrate from local hospital record platforms to the PBTA.

Through RADIANT, CBTN transforms how we approach diagnosis and treatment planning, providing researchers with unprecedented access to AI-ready datasets, advanced tools, and leading-edge resources. With continued support from Bridge To A Cure and others, RADIANT will set a new standard for personalized care, bringing us closer to a future where every child diagnosed with a brain tumor doesn’t just survive but thrives.

What Lies Ahead

Over the past seven years, Bridge To A Cure Foundation has transformed and united the childhood cancer community. We’ve built a powerful network of researchers, doctors, families, and advocates, all working to end childhood brain cancer.

During this time, we’ve seen significant strides in advancing scientific research and fostering an environment where innovation and hope flourish. The accomplishments of 2024 are the culmination of many years of hard work, determination, and a shared belief that we can overcome the challenges that have long hindered the progress that keeps us from ending this brutal disease. Bridge To A Cure has created real, lasting change, from breakthroughs in data-driven research and patient care to new partnerships with leading research institutions, tech companies, and the federal government. We are poised to make even more incredible strides with these achievements as the framework for new advancement.

For 2025 and beyond, Bridge To A Cure is urging foundations and philanthropists that share our vision to invest $100 million in dedicated brain tumor research funds. By mirroring the collaborative success of our research institution partners, these funds will empower scientists to bypass traditional barriers and accelerate groundbreaking therapies and prevention strategies. And, by supporting this groundbreaking research, we’re investing in a brighter future for families. Every contribution, no matter the size, translates into tangible progress. Your generosity fuels real hope that we will conquer childhood brain tumors and protect the health and happiness of our children.

The fight against childhood cancer is a complex challenge requiring a united and strategic approach. While numerous passionate organizations are dedicated to this cause, a fragmented landscape can hinder progress. As we mentioned in our October blog, researchers, clinicians, patient advocates, and technology companies are already banding together to pool their knowledge and expertise to reimagine how pediatric disease research is conducted. This same collaborative spirit driving the sea change in research can also work when it comes to philanthropy and philanthropic groups you support.

To achieve a future where childhood cancer is no longer a life-threatening disease, we must:

• Support Innovative Research: Fund groundbreaking research projects that have the potential to revolutionize real-time, real-world treatment.
• Advocate for Policy Change: Work together to influence healthcare policies that prioritize pediatric cancer research.
• Foundational Collaboration: Partner with other foundations working toward the same goal to amplify impact on pediatric cancer research.

One possible path forward is by pooling resources and effort. In cooperation with other organizations, Bridge To A Cure Foundation can significantly enhance its impact and accelerate the pace of discovery.

The Missing Pieces

One of the biggest challenges in the pediatric cancer research field is the lack of coordination among non-profit organizations. This fragmentation can lead to inefficiencies:

• Redundancy in fundraising efforts: Competing for limited resources can dilute the impact of individual organizations.
• Duplication of research: Overlapping research projects can slow overall progress.
• Operational inefficiencies: Smaller organizations may struggle with administrative burdens, diverting funds from research.

A Call for Collaboration

Inspired by the collaborative spirit of the scientific community, we believe that philanthropic organizations can achieve an even more significant impact. As the pediatric cancer research landscape evolves, there is a growing need for philanthropic organizations to work together more closely. These organizations can significantly impact the field by aligning their efforts and pooling resources. One key challenge is to ensure that funding is directed towards the most promising research projects and that there is minimal duplication of effort.

A Shared Vision for the Future

A unified approach to philanthropy can help to accelerate progress towards a cure for childhood cancer.

By supporting common goals and priorities, philanthropic organizations can maximize their impact and ensure their contributions are used effectively.

Finally, one novel solution may be to convince these large research institutions with substantial excess reserves to establish a dedicated $100 million pediatric brain tumor fund. This fund could enable scientists to focus on innovative therapies and prevention strategies, bypassing bureaucratic hurdles and traditional research models. This bold idea has the potential to significantly improve outcomes for children battling brain tumors, offering hope where it was once scarce.

We enthusiastically invite philanthropic organizations to join us to accelerate scientific discovery, influence healthcare policies, and uplift families during their most challenging times. We now know that the pediatric cancer researcher community can do it successfully. Together, nonprofits and philanthropists can advance a future where childhood cancer is no longer a mortal threat, but a treatable disease.

The landscape of pediatric cancer research is undergoing a dramatic transformation, driven by a determined spirit of collaboration, data sharing, and technological innovation. This shift is fueled by a growing understanding of the unique challenges faced by young patients and a collective determination to find cures. Bridge To A Cure Foundation played a leading role defining and transforming the approach to pediatric brain cancer.

A Shared Vision

In recent years, researchers, clinicians, and patient advocates have formed powerful alliances to accelerate the speed at which information is gathered, organized, and shared. Organizations like Bridge To A Cure partner, The Children’s Brain Tumor Network (CBTN), have fostered cooperation and accelerated research so that scientists can identify promising findings, uncover new insights, and develop more effective treatments by sharing data, expertise, and resources.

The Power of Data

Data is the lifeblood of modern research, and the pediatric cancer community has recognized its immense potential.

Initiatives like the Pediatric Brain Tumor Atlas (PBTA) are where support from Bridge To A Cure ,and other nonprofits, can have a greater impact. The PBTA is a groundbreaking initiative that leverages the power of multi-modal data from over 8,000 enrollees. This rich dataset, encompassing genomic information, clinical records, digital imaging, and more, provides a comprehensive view of each patient’s journey. By unlocking the insights hidden within this data, researchers can develop more targeted and less toxic therapies, ultimately improving patient outcomes.

Government Support and Innovation

Governments worldwide have also recognized the importance of supporting pediatric cancer research. Increased funding for research initiatives has allowed scientists to explore new avenues, such as immunotherapy and gene therapy. Additionally, advancements in artificial intelligence and machine learning have opened new possibilities for drug discovery, clinical trial design, and personalized medicine.

Bridge to a Cure is proud to support collaborative efforts that are transforming the landscape of pediatric cancer research.

The Gabriella Miller Kids First Act has created a powerful platform for researchers to share data, insights, and expertise. By making the CBTN PBTA dataset accessible to the global research community, we are fostering innovation and accelerating the pace of discovery. Together, we can build a future where every child has the chance to thrive.

A Culture of Collaboration

The culture of pediatric cancer research has evolved significantly, with a greater emphasis on collaboration and open science. This movement away from competitive research models in pediatric research has paved the way to real progress in pediatric cancer research and understanding congenital disorders. Researchers are increasingly sharing their findings and working together to address complex challenges. Forums like the Bridge To A Cure-sponsored Children’s Brain Tumor Network Summit, attended by hundreds of scientists and technologists in Virginia this past October offer opportunities for the pediatric brain tumor research community to explore ideas together. This collaborative approach removes traditional research barriers and accelerates the pace of discovery.

The advancements in pediatric brain tumor research in recent years is directly attributed to a collaborative approach within and across institutions. Childhood cancer nonprofits should do the same.  Next month’s blog will begin to explore this opportunity.

Exploring the Power of Non-Toxic Treatments

September is Childhood Cancer Awareness Month, a time to spotlight the tens of thousands of children and families immersed in the devastating reality of this catastrophic disease. And, while traditional treatments like chemotherapy and radiation have increased survival chances for many forms of the disease, there are prevalent, sometimes severe, long-term health concerns that linger long after these kids grow into adulthood. Undeniably, there is a need for safer, more effective options.

Bridge To A Cure Foundation invests in developing nontoxic treatments for pediatric patients, precision medicine powered by AI discovery, and therapies that tap into the body’s systems to fight against childhood cancer.

Angiogenesis: Cutting Off Cancer’s Blood Supply

Of the many promising approaches Bridge To A Cure is funding, angiogenesis is the most exciting. Angiogenesis involves targeting the blood vessels that nourish tumors. Cancer cells are notorious for hijacking the body’s natural process of blood vessel growth to sustain themselves. By disrupting this process, researchers hope to starve tumors and prevent their spread.

Angiogenesis inhibitors are medications that block the signals that encourage blood vessel growth. These drugs can be used alone or in combination with other treatments. While still under development, early studies suggest that angiogenesis inhibitors may have fewer side effects than traditional chemotherapy, making them a more tolerable option for children.

Precision Medicine: Tailoring Treatment to the Individual

Precision medicine, also known as personalized medicine, is a revolutionary approach that aims to tailor treatments to the specific genetic makeup of a patient’s cancer. This approach recognizes that no two cancers are alike; therefore, a one-size-fits-all approach may not be optimal.

AI-powered discovery is playing a crucial role in advancing precision medicine. By analyzing vast amounts of genetic data, AI algorithms can identify unique genetic mutations associated with different types of cancer and what treatments have been shown to work best for a specific mutation. This information can help doctors select each patient’s most effective treatment options.

For example, if a specific genetic mutation drives a child’s cancer, researchers may be able to develop targeted therapies that specifically attack that mutation, minimizing damage to healthy cells. This personalized approach can improve treatment outcomes and reduce side effects.

Immunotherapy: Unleashing the Body’s Inherent Defense

Immunotherapy is another promising avenue for treating childhood cancer. This approach leverages the body’s immune system to fight cancer cells. The immune system is a complex network of cells and proteins that help protect the body from infections and diseases. Unfortunately, cancer cells can sometimes evade the immune system’s detection or even manipulate it to their advantage.

Immunotherapy aims to restore the immune system’s ability to recognize and attack cancer cells. One type of immunotherapy involves antibodies that help activate the immune system’s T-cells, specialized cells that can destroy cancer cells. Another approach involves removing immune cells from the patient’s body, modifying them in the laboratory to make them more effective against cancer, and reintroducing them back into the patient.

While immunotherapy has shown remarkable success in treating certain adult cancers, its application in childhood cancer is still being explored. However, early studies suggest immunotherapy may induce long-lasting remissions or even cures in some children. 

A Brighter Future

The mountain of challenges posed by childhood cancer is indeed steep, but the development of nontoxic treatments offers hope for a brighter future. Angiogenesis, precision medicine powered by AI discovery, and immunotherapy promise to provide safer and more effective options for children faced with this devastating disease.

This latest investment by Bridge To A Cure exemplifies our commitment to collaboration, open science, and strategic partnership to end childhood cancer. With support from people like you, Bridge To A Cure drives significant progress in childhood cancer research by fostering a more united and efficient research community. Our goal of fulfilling the promise starts with accelerating the development of innovative therapies but won’t end until we secure a future where childhood cancer ceases to exist. Together, we are bridging the gap to deliver better treatments and cures.

Childhood cancers are complex and multifaceted challenges that require innovative and comprehensive approaches. While significant progress has been made in recent years, many of these cancers remain challenging to treat, and the need for groundbreaking research is more urgent than ever. One promising strategy is multidisciplinary research, a collaborative approach that brings experts from various fields together to tackle these complex challenges.

Take A Close Look at Multidisciplinary Research

In multidisciplinary research, clinicians share research goals and work on the same problem from their discipline’s perspective. This collaborative approach allows for a more comprehensive and in-depth understanding of the disease, as each discipline can contribute unique insights and expertise.

The findings from each discipline can be complementary, and a particular specialty can analyze each aspect uniquely. This can be necessary to answer complex research problems that cannot be adequately addressed by a single discipline alone. For example, a pediatric oncologist might focus on the biological aspects of a tumor. At the same time, a researcher might seek to understand better the patient’s genetic profile to slow tumor growth.

Benefits

Multidisciplinary research offers several key benefits:

• Increased Efficiency: By working together, researchers can avoid duplication of efforts and maximize the use of resources.
• Enhanced Innovation: Cross-pollinating ideas and perspectives can lead to innovative approaches and breakthroughs that might not be possible with a single disciplined approach.
• Improved Patient Outcomes: Multidisciplinary research can ultimately lead to better treatments and improved outcomes for children with cancer.

Multidisciplinary Research in Patient Care

A multidisciplinary approach to patient care can lead to a more thorough evaluation, accurate diagnosis, and tailored treatment plan.

For example, Multidisciplinary rounds (MDR) constitute a patient-centered care model wherein professionals from diverse disciplines collaborate in real-time to provide specialized expertise. These can include care partners, hospitalists, nurses, and pharmacists.

MDRs can help to ensure that all aspects of a child’s care are considered, from their physical and emotional needs to their social and financial well-being. This collaborative approach can also help to reduce the stress and anxiety experienced by families, as they know that their child is receiving the best possible care.

The Role of Bridge to a Cure Foundation

Bridge to a Cure Foundation supports multidisciplinary research into childhood cancers. By funding innovative research projects and fostering collaborations between researchers, we are helping to advance our understanding of these complex diseases and develop new and more effective treatments.

Through our efforts, with the support of people like you, Bridge To A Cure hopes to significantly impact the lives of children with cancer and their families.

Childhood cancer is a complex disease that can manifest in various forms, each with its unique characteristics and challenges. Traditional research methods have provided valuable insights but often fail to unravel the intricate biological mechanisms underlying these diseases fully. To address this, scientists are turning to a groundbreaking approach known as multiomics.

What is Multiomics?

Multiomics is a comprehensive research strategy that simultaneously analyzes multiple layers of biological information, including:

• Genomics: The study of an organism’s complete set of DNA.
• Transcriptomics: The study of the RNA molecules produced by an organism.
• Proteomics: The study of the proteins produced by an organism.
• Metabolomics: The study of the small molecules involved in metabolism.

By integrating these different data sets, researchers gain a more holistic understanding of the biological processes involved in disease development and progression.

Bridge To A Cure Foundation and Multiomics Research

The Bridge To A Cure Foundation is committed to advancing childhood cancer research and improving treatment outcomes. By supporting multiomics research, the foundation is helping to drive significant advancements in this field.

One key benefit of multi-omics research is its ability to identify new therapeutic targets. By analyzing childhood cancer cells’ genetic, transcriptomic, proteomic, and metabolomic profiles, researchers can uncover specific molecular pathways essential for tumor growth and survival. This information can then be used to develop targeted therapies that selectively attack cancer cells while minimizing damage to healthy tissues.

Another important application of multiomics research is the development of personalized treatment plans. Traditional treatment approaches often involve a one-size-fits-all approach, which may only be optimal for some patients. Multiomics can help identify biomarkers predicting how a patient will respond to a particular treatment. This information can be used to tailor treatment plans to each patient’s specific needs, potentially improving outcomes and reducing side effects.

Challenges and Future Directions

While multiomics research holds great promise for advancing childhood cancer research, it also presents significant challenges. One of the main challenges is the sheer volume of data generated by these studies. Analyzing and interpreting this data requires sophisticated computational tools and expertise, which don’t come cheaply. Additionally, there is a need for standardized protocols and data-sharing initiatives to ensure that multiomics data can be effectively compared and integrated across different research groups.

Bridge To A Cure is tackling these complex challenges head-on by funding the Children’s Brain Tumor Network (CBTN) with $200,000 to explore data-driven solutions, including AI-powered tools, to streamline the extraction and analysis of electronic health records (EHR) data.

The Bridge To A Cure Foundation believes in advanced research approaches, like multiomics research, working tirelessly to improve the lives of children battling cancer. By supporting this groundbreaking approach, we can accelerate the development of new and effective therapies that ultimately lead to a cure.